Calder Biosciences, Inc.
- Home
- Companies
- Calder Biosciences, Inc.
- Products
- Calder - Universal Flu Vaccine Program
Calder - Universal Flu Vaccine Program
Pandemic influenza poses a real and present threat of outbreaks with high fatality rates. Each year, seasonal flu causes: 9M-45M illnesses – causing a substantial loss working days and a major burden on society. 140K-800k hospitalizations - loss of independence, high burden on community and healthcare system. 12K-80k deaths, primarily in the elderly.
Most popular related searches
- Seasonal flu vaccines are poorly effective ranging from 10% to 60% efficacy, depending on seasonal match; pandemic strains cannot be predicted.
- Calder’s universal flu vaccine will achieve pandemic preparedness and simultaneously reduce seasonal disease burden, by inducing antibodies to parts of a viral surface protein common to all strains of influenza
- Variable ”Head” domain of the HA protein is removed (“Headless”); focuses antibody responses on the highly conserved “Stalk”
- Headless has the greatest potential for universal protection